Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemvidutide in Noncirrhotic MASH
NCT07795164Phase 3Recruiting
- Sponsor
- Altimmune, Inc.
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Altimmune, Inc.. Started Jul 2026; status: recruiting.
02
Drugs
pemvidutide
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07795164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07795164.